you probably know, armed antibodies and bispecifics are the way forward when it comes to antibody therapeutics. Leading the way are companies such as Genentech, Amgen and Seattle Genetics, who are all attending this year's European Antibody Congress. Meaning, that you have a chance to meet them!
Andrew Polson, Principal Scientist at Genentech will be sharing with us the development of anti-CD3 bispecifics, which may be used for the treatment of haematological malignancies.
Matthias Klinger, Principal Scientist – BiTE Immunology from Amgen will
be giving us an update on the Bispecific T-Cell Engagers (BiTE®) in development, and an update on clinical development programs of BLINCYTO®, the first and only FDA-approved Bispecific CD19-directed CD3 T-cell Engager.
Patrick Burke, Associate Director from Seattle Genetics will give us an exciting insight into their recent work on the development of novel quaternary ammonium linkers for antibody-drug conjugates.
Hans-Peter Gerber, Vice President & CSO of Pfizer Worldwide Research & Development, will be opening the congress with a presentation on ADC combination therapy and what we can expect in this industry over the next years, and Janice Reichert, Editor-in-chief of mAbs and Executive Director of The Antibody Society will be giving a closing keynote on all her inside knowledge of antibodies to watch for 2017 and beyond.
The World Immunotherapy Congress will also be launching in Basel this year as a co-located event. Hear all the hottest news from key players in the immunotherapy industry such as Juno Therapeutics, Memorial Sloane Kettering Cancer Centre, Immunocore, Cellectis, Roche and AbbVie.
With these scientists, just a few of the 80+ strong speaking faculty, it would seem silly to miss out on the opportunity to network and hear from these thought leaders and decision makers. Register now to join them.
*Take advantage of our early bird discount and book before October 7th to save €525*
To find out more, download the brochure to learn more about the incredible speakers we have this year, and all the other opportunities the event can provide.